Book a Test

The MoleculeDx Test

Everything you need to know about our Fusion-detect™ blood-based liver cancer screening test.

 

What We Test For

Detecting HCC Before Symptoms Appear

The MoleculeDx test screens specifically for hepatocellular carcinoma (HCC) — the most common form of primary liver cancer, accounting for 75–85% of all liver cancer cases in the US.

We analyze circulating tumor DNA (ctDNA) in your blood for HCC-specific fusion gene signatures. These molecular markers appear in the bloodstream at very early tumor stages — often 12–18 months before imaging can detect a tumor.

Who should get tested? Anyone with risk factors including: chronic hepatitis B or C, cirrhosis, non-alcoholic fatty liver disease (NAFLD/NASH), heavy alcohol use (past or present), family history of liver cancer, or Type 2 diabetes with liver disease.

Performance Data

Clinical Validation Results

MetricFusion-detect™ (MoleculeDx)Standard AFP TestUltrasound Alone
Overall Accuracy96.7%~52%~63%
Sensitivity (Early Stage)94.2%~41%~47%
Specificity98.1%~87%~91%
Detects Stage I HCC✓ YesOften NoOften No
Invasive ProcedureNoneNoneHospital Req.
At-Home Collection✓ YesNoNo
Result Turnaround24 Hours24–48 hrs1–2 weeks
The MoleculeDx test is a screening tool, not a diagnosis. A positive result will be followed up with your physician to confirm findings via imaging or specialist consultation.

Pricing

Transparent, Affordable Pricing

No hidden fees. No surprise bills. And our team will verify your insurance coverage for free before you schedule.

Most Popular

Home Visit

$130 / test

Single liver cancer screening test with full digital report.

  • At-home phlebotomy visit
  • Fusion-detect™ analysis
  • Digital results in 24 hrs
  • Pathologist-reviewed report
  • Follow-up consultation line
  • Easy and Most convient

Most Affortable

Visit UPMC

Custom  / test

Single liver cancer screening test with full digital report.

  • Patient must visit nearest UPMC
  • Fusion-detect™ analysis
  • Digital results in 72 hrs
  • UPMC Pathologist-reviewed report
  • Follow-up consultation line
  • Sample collection Process done by UPMC
Find UPMC Near You

The test screens for hepatocellular carcinoma (HCC) — the most common form of primary liver cancer. We analyze your blood for fusion gene biomarkers that are specific to early-stage liver cancer. These markers appear in the bloodstream significantly earlier than tumors become visible on ultrasound or CT scans.

The test requires only a standard venipuncture — the same blood draw you’d receive at any clinic or doctor’s office. It is not a biopsy. There’s no tissue removal, no surgery, and no imaging. Most people describe it as mild and brief. The certified phlebotomist comes to your home and the draw itself takes 5–10 minutes.
 
The Fusion-detect™ test achieves 96.7% overall accuracy, 94.2% sensitivity, and 98.1% specificity in clinical validation. A liver biopsy is considered definitive for diagnosis — but it is invasive, carries risks of bleeding and infection, and is not suitable as a screening tool. Our test is a screening tool that identifies patients who need further investigation. For a positive MoleculeDx result, we facilitate referral to a physician for confirmatory imaging or biopsy if warranted.
 
MoleculeDx is accepted by most major US insurers including UnitedHealth, Anthem/Blue Cross Blue Shield, Aetna, Cigna, Humana, and UPMC Health Plan. Medicare Advantage plans are also accepted. Coverage for cancer screening tests varies by plan and diagnosis code. Our team will verify your specific coverage for free before you book — contact us or check at booking.moleculedx.com.
 
Results are delivered digitally within 24 hours of sample receipt at our laboratory. You’ll receive a secure notification by email or SMS with access to your full clinical report. For results that require attention, a care coordinator will reach out to you directly within the same window to guide next steps.
 
A positive result does not mean you have cancer — it means biomarkers were detected that warrant further evaluation. Our care coordinator will contact you immediately to explain your results in plain language and help arrange follow-up imaging (typically an MRI or CT) and referral to a hepatologist or oncologist. We work with your existing providers or can refer you to UPMC specialists depending on your location.
 
Yes. Through our exclusive partnership with University of Pittsburgh Medical Center, patients can walk into any UPMC facility and request the MoleculeDx liver cancer screening test. UPMC physicians can also order it directly through UPMC’s Epic EHR system. Results are delivered within 24 hours and integrated directly into your UPMC health record.
 
We partner with Portamedic (portamedic.com) and Travalab (travalab.com) — two of the largest and most trusted mobile phlebotomy networks in the United States. All phlebotomists are nationally certified (CPT or equivalent) and undergo background checks and quality assurance training specific to MoleculeDx sample handling protocols.
 
No referral is required to book a self-pay test. However, insurance coverage typically requires an ordering physician. If you don’t have a primary care provider, our care coordinators can help connect you with a telemedicine physician who can provide the order — often within the same day.
 
At-home phlebotomy through Portamedic and Travalab is available across all 50 US states, though coverage in rural areas may require advance scheduling of 3–5 days. Walk-in testing is currently available exclusively at UPMC locations. We are actively expanding our clinical site network — check booking.moleculedx.com for your specific zip code coverage.
 

First-in-class blood-based liver cancer early detection. Powered by Fusion-detect™ AI genomics technology.

Linkedin X-twitter Tiktok Youtube Facebook Instagram

Company

For Patients

CONTACTS

© 2026 MoleculeDx Inc. All rights reserved.

This test is not a substitute for medical diagnosis. Consult your physician with all results.